Subcutaneous B16F10 melanoma tumors were grown to 150 mm3 then injected I.T. with selective agonists targeting TLR3, TLR7or TLR9, or vehicle control respectively (Figure 1A). This evidence concerns the gene TLR9 and melanoma.